Menu
Founded in 2005 from Dr. P.Y. Reddy’s belief that chemistry is transformative, Sapala Organics began as a trusted partner for Japan’s pharma industry. His vision, alongside Dr. Yogesh Sanghvi’s expertise in nucleic acid chemistry, fueled a journey into new frontiers of medicinal chemistry.
With over a century of combined experience across 18 labs, our team doesn’t just solve problems; we redefine possibilities, molecule by molecule. Our recent partnership with Suven Pharma further deepens our CDMO and medicinal chemistry focus, leading us into the future.
Our guiding question remains: Where next? We’ll follow the chemistry—it lights our path forward.
Sapala Organics is now a proud subsidiary of Suven Pharmaceuticals Limited, a Global Pharma CDMO and a specialty chemical innovator. With this acquisition, Suven aims to leverage Sapala’s expertise in the high-growth oligonucleotide and Nucleic Acid building blocks sector, particularly in advanced oligo technologies and complex Amidite and nucleoside building blocks. Sapala’s unique capabilities and proven track record in complex synthesis make it a strategic fit for Suven’s vision of expanding in niche technology platforms. This coming together unlocks manufacturing scale-up and global commercialization capabilities, enhancing Sapala’s growth and elevating its pharmaceutical offerings.
To be recognized as an able, trusted & socially responsible scientific organization.
To build a sustained relationships with business partners by offering high quality professional services through Innovation in Chemical Science & Drug discovery Technologies.
Roman philosopher Cicero said, ‘As long as there is life, there is hope.’ This truth inspires our commitment to providing hope through next-gen genetic care and small molecule NCE.
Every day, Sapala’s 250+ employees quietly contribute to shaping a future full of possibilities.
As pioneers in nucleic acid chemistry, we bring extensive expertise and a partnership ethos built on trust, making us a reliable CRO & CDMO partner for drug discovery.
We look forward to helping you ride the next wave of genetic therapies.
Our management team is a blend of visionary leaders with deep-rooted expertise in chemical development and manufacturing. Like the backbone of a DNA strand, they provide the structure and guidance that shape our strategic vision, ensuring operational excellence at every step. Their decades of experience fuel Sapala’s growth, leading us to break new ground in the chemical industry.
Our research and development team forms the core of our innovation engine. Just as nucleic acids are the blueprint of life, their work lays the foundation for Sapala’s leadership in medicinal and nucleic acid chemistry. Constantly pushing the boundaries of what’s possible, they develop cutting-edge solutions that redefine the CDMO landscape and drive our success.
At Sapala, every process is governed by industry-grade quality standards. And we hold accreditations like ISO 9001, ISO 27001 and others. As we continue to explore the depths of chemistry, our commitment to adhering to the highest quality standards only intensifies further.
At Sapala, we are committed to creating a positive impact beyond business through our comprehensive Corporate Social Responsibility (CSR) and sustainability initiatives. Our focus is on empowering communities and ensuring environmental stewardship.
We actively contribute to education, healthcare, and skill development programs in the regions we operate, driving social progress and sustainable development. In alignment with our sustainability goals, we continuously optimize our operations to reduce our environmental footprint, from energy-efficient practices to responsible waste management.
Our name, SAPALA, draws from the power of three revered Indian goddesses—Saraswathi, Parvathi, and Lakshmi—embodying knowledge, strength, and well-being.
Saraswathi fuels our pursuit of knowledge and innovation; Parvathi represents collaborative strength, essential in overcoming scientific challenges; and Lakshmi signifies prosperity and health, guiding us toward sustainable impact.
Together, these ideals form SAPALA’s guiding principle: “Well-Being Through the Power of Knowledge,” driving us to impact lives positively, one discovery at a time.
Did You Know…
Dr. Paidi Yella Reddy, the visionary behind Sapala Organics Pvt. Ltd., has led a pioneering career in organic chemistry and pharmaceutical R&D. Since founding Sapala Organics in 2005, Dr. Reddy has built an innovative company grounded in his extensive experience, particularly his role as Director of R&D with Aisin Cosmos R&D Co., Ltd., part of the Toyota Group. Known for his pivotal role in introducing DSSC technology to India, Dr. Reddy has spent over 20 years spearheading collaborative research across prestigious institutions, including IICT in India and EPFL in Switzerland. Additionally, he has shared his expertise as a Visiting Professor at the University of Tokyo.
A Ph.D. in organic chemistry from the National Chemical Laboratory in Pune, Dr. Reddy’s research includes work on synthesizing natural products via photochemistry. His postdoctoral research at the Nagoya Institute of Technology in Japan explored advanced materials for solar cells and fluorescence applications in biological sciences. Dr. Reddy’s impressive body of work includes over 70 publications in international journals and more than 40 patents, reflecting his lasting impact on scientific research and application.
Dr. V. Prasada Raju is the Managing Director of Suven Pharma and Cohance Lifesciences.
Dr Prasada Raju served as an Executive Director at Granules India Ltd., where he played a key role in driving growth strategy, managing the product portfolio, overseeing scientific and regulatory affairs, handling intellectual property matters, and leading new business initiatives. Moreover, he was instrumental in establishing R&D and Greenfield projects within the company. As part of his responsibilities, he served on the Boards of Granules Omnichem Pvt Ltd (Vizag, India), Granules Pharmaceuticals Inc. (DC, USA), and USpharma Ltd (FL, USA).
Dr Prasada Raju’s impressive academic background includes a PhD in chemistry, a PG Dip in patent law, and specialised training in material sciences at IIT, Chicago, USA. He is also an alumnus of the Senior Management Program at IIMC (Indian Institute of Management). With over 30 years of techno-commercial experience in the pharmaceutical industry, spanning various aspects of the value chain, he has held leadership roles at Granules India Limited and Dr Reddy’s Laboratories. During his tenure at Dr. Reddy’s, from 1994 to 2012, he provided technical, strategic, and operational leadership in uniquely challenging positions within the pharma sector.
Overall, Dr V. Prasada Raju’s extensive experience and expertise make him a highly respected and accomplished figure in the pharmaceutical industry, where he continues to make significant contributions in his current roles.
Mr Himanshu Agarwal brings with him 29 years of professional experience and prior to joining Suven, he held leadership roles in ICI India, Astra Zeneca Pharma, Akzo Nobel India, Huhtamaki Oyj and Bennett, Coleman & Co. Ltd. Himanshu brings broad Global and Indian experience in Finance, M&A, Strategy, Investor relations, operations and technology enablement in coatings, chemicals, Pharma, Packaging and Media Industries.
He has successfully led many strategic initiatives including business-enabled finance transformation, profit turnaround, value chain optimisation and several M&A deals and integrations. He has enabled technology deployment from ERP to BOTs, enabling process transformation and simplification.
Himanshu is a rank-holder Chartered Accountant, a company secretary, a cost and management accountant and has been awarded best CFO by the Institute of Chartered Accountants of India.
Atin is a Director at Advent International and covers Technology Investments across US & India and Healthcare investments in India. He joined Advent in 2019 from Bain Capital, where he spent over five years working across Technology and Healthcare investments. Prior to that, he has worked at Bain & Company (Consulting) and Accenture (Technology).
Atin has worked on numerous investments during his time at Advent and Bain Capital including Encora, Tredence, Brillio, QuEST Global, Bharat Serums & Vaccines, Cohance Lifesciences, Suven Pharma, Apollo 24×7 amongst others. He currently serves on the Boards of Encora, Tredence, and Sapala Organics.
Mr. K G Ananthakrishnan is an Independent Director of the Company with effect from 29th September 2023. Throughout his illustrious career, Mr Ananthakrishnan has held influential positions, including Director General of the Organization of Pharmaceutical Producers of India (OPPI) and Co- Chair of the Pharma Committee at the Confederation of Indian Industry (CII), where he played a pivotal role in shaping vital policy initiatives.
Educationally, Mr. Ananthakrishnan holds a master’s in marketing management from Jamnalal Bajaj Institute of Management Studies, Mumbai, and a Bachelors in Science from Osmania University, Hyderabad. To further enhance his knowledge and skills, he has completed Executive Development Programs at the Wharton Business School, USA, and the Finance for Non-Finance Program at INSEAD, France.
With over 40 years of progressive leadership experience in the pharmaceutical market, Mr. Ananthakrishnan’s career began in 1976 with Novartis India Limited. He then held key positions at Pharmacia India, Pfizer India Ltd., and Fulford (India) Ltd. Notably, during his tenure as Vice President and Managing Director of the South Asia Region at MSD, he successfully transformed the company into a rapid-growth pharmaceutical powerhouse.
Dr. Sanghvi is a leader in nucleoside and oligonucleotide research with a distinguished career at ICN Pharmaceuticals and Isis (Ionis) Pharmaceuticals. His contributions include developing antiviral and antitumor agents and oligonucleotide-based therapeutics. Sapala is represented by Rasayan–founded by Dr Sanghvi in 2003–focuses on consulting, outsourcing, and supplying Nucleic Acid products.
Principal Scientist
AGM – Production
Sudhakar Reddy is an accomplished production specialist with extensive expertise in API and intermediate synthesis, process optimization, and commercial-scale manufacturing.
Dr. Vijay Kumar is a specialist in organic synthesis, process chemistry, and eco-friendly photochemical processes, with hands-on experience in GMP and regulatory compliance.
Dr. Vishweshwar Rao is a seasoned medicinal chemist with expertise in natural product synthesis, drug design, and FTE/FFS project execution for diverse pharmaceutical needs.
